Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Waldo

Showing results (181-190 of 231) with videos related to

Pageof 24
Sort By:
Molecular Pharmacology|October 23, 2002
Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonistGary L Waldo, James Corbitt, José L Boyer, et al.
American Heart Journal|July 2, 2005
Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) studyJohn P DiMarco, Gregory Flaker, Albert L Waldo, et al.
Circulation|January 1, 1991
Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study GroupR W Henthorn, A L Waldo, J L Anderson, et al.
Circulation|December 1, 1989
Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study GroupJ L Anderson, E M Gilbert, B L Alpert, et al.
Circulation|January 20, 2005
Role of permanent pacing to prevent atrial fibrillation: science advisory from the American Heart Association Council on Clinical Cardiology (Subcommittee on Electrocardiography and Arrhythmias) and the Quality of Care and Outcomes Research Interdisciplinary Working Group, in collaboration with the Heart Rhythm SocietyBradley P Knight, Bernard J Gersh, Mark D Carlson, et al.
American Journal of Physiology. Heart and Circulatory Physiology|April 17, 2007
Effects of sterile pericarditis on connexins 40 and 43 in the atria: correlation with abnormal conduction and atrial arrhythmiasKyungmoo Ryu, Li Li, Celeen M Khrestian, et al.
Circulation. Arrhythmia and Electrophysiology|March 16, 2018
Incidence and Clinical Significance of New-Onset Device-Detected Atrial Tachyarrhythmia: A Meta-AnalysisMark N Belkin, Cesar E Soria, Albert L Waldo, et al.
The Journal of Thoracic and Cardiovascular Surgery|November 1, 2020
Three-year outcomes of the postapproval study of the AtriCure Bipolar Radiofrequency Ablation of Permanent Atrial Fibrillation TrialPatrick M McCarthy, Marc Gerdisch, Jonathan Philpott, et al.
The American Journal of Cardiology|May 15, 1995
Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD trial)A L Waldo, A J Camm, H deRuyter, et al.
Circulation|January 1, 1992
Ventricular tachycardia rate and morphology determine energy and current requirements for transthoracic cardioversionR E Kerber, M G Kienzle, B Olshansky, et al.
Pageof 24

Showing results (181-190 of 231) with videos related to

Sort By:
Pageof 24
Molecular Pharmacology|October 23, 2002
Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonistGary L Waldo, James Corbitt, José L Boyer, et al.
American Heart Journal|July 2, 2005
Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) studyJohn P DiMarco, Gregory Flaker, Albert L Waldo, et al.
Circulation|January 1, 1991
Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study GroupR W Henthorn, A L Waldo, J L Anderson, et al.
Circulation|December 1, 1989
Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study GroupJ L Anderson, E M Gilbert, B L Alpert, et al.
Circulation|January 20, 2005
Role of permanent pacing to prevent atrial fibrillation: science advisory from the American Heart Association Council on Clinical Cardiology (Subcommittee on Electrocardiography and Arrhythmias) and the Quality of Care and Outcomes Research Interdisciplinary Working Group, in collaboration with the Heart Rhythm SocietyBradley P Knight, Bernard J Gersh, Mark D Carlson, et al.
American Journal of Physiology. Heart and Circulatory Physiology|April 17, 2007
Effects of sterile pericarditis on connexins 40 and 43 in the atria: correlation with abnormal conduction and atrial arrhythmiasKyungmoo Ryu, Li Li, Celeen M Khrestian, et al.
Circulation. Arrhythmia and Electrophysiology|March 16, 2018
Incidence and Clinical Significance of New-Onset Device-Detected Atrial Tachyarrhythmia: A Meta-AnalysisMark N Belkin, Cesar E Soria, Albert L Waldo, et al.
The Journal of Thoracic and Cardiovascular Surgery|November 1, 2020
Three-year outcomes of the postapproval study of the AtriCure Bipolar Radiofrequency Ablation of Permanent Atrial Fibrillation TrialPatrick M McCarthy, Marc Gerdisch, Jonathan Philpott, et al.
The American Journal of Cardiology|May 15, 1995
Survival with oral d-sotalol in patients with left ventricular dysfunction after myocardial infarction: rationale, design, and methods (the SWORD trial)A L Waldo, A J Camm, H deRuyter, et al.
Circulation|January 1, 1992
Ventricular tachycardia rate and morphology determine energy and current requirements for transthoracic cardioversionR E Kerber, M G Kienzle, B Olshansky, et al.
Pageof 24